BioWorld-International-2010-10-13
Synosia Therapeutics Nabs Potential $725M Pact with UCB
Synosia Therapeutics Nabs Potential $725M Pact with UCB
LONDON Synosia Therapeutics sealed a $725 million pact on its two lead drugs for treating Parkinson's disease with UCB Pharma, and announced the closing of a third round funding of $30 million. (BioWorld International)

